amfAR announces inaugural Mathilde Krim Fellowship Awards for AID...(han twenty antiretroviral drugs patients...),Health

Date:1/4/2008

han twenty antiretroviral drugs, patients often develop drug resistance to all currently available drug classes, including the two currently available types of reverse transcriptase inhibitors (RTIs). Dr. Marchand and his colleagues have discovered a new type of compound that blocks the reverse transcription process but differs chemically from existing RTIs. The new compound is effective against normal as well as drug-resistant virus and thus may be exceedingly useful in guiding efforts to devise new drug treatment strategies. Dr. Marchand will characterize more closely the mechanism of action of this new compound.

Morgane Rolland, Ph.D./Mentor: James Mullins, Ph.D.
University of Washington, Seattle, WA
$125,000

Maintenance of drug resistance mutations and HIV-1 evolutionary adaptation: When HIV reproduces, mutated versions of the virus can arise that are less susceptible to anti-HIV drug therapy. There is a fitness cost to the virus, however, since mutated HIV generally reproduces less efficiently. Despite being weaker, drug-resistant mutant HIV can persist in individuals and be transmitted to others, thus perpetuating treatment difficulties. Dr. Rolland hypothesizes that when the virus mutates to avoid drug therapy, it simultaneously makes other mutations that strengthen its ability to reproduce, outweighing the weakening effects of the therapy-evasion mutations. Future developments in HIV drug therapy will be guided by the results of Dr. Rollands research.

Rogier Sanders, Ph.D./Mentor: Ben Berkhout, Ph.D.
Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
$125,000

Generation of stable HIV-1 Env trimers through virus evolution: AIDS vaccine development has been hampered by the difficulty in producing a protein in the lab that mimics proteins on the surface of HIV. Such proteins could theoretically be used to make an AIDS vaccine. Researchers until now have been plagued by d
'/>"/>

Contact: Donald Kaplan donald.kaplan@amfar.org 212-806-1602 amfAR, The Foundation for AIDS Research Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. amfARs MSM Initiative Seeks Proposals From Front-Line Groups Working on HIV in Developing Countries
2. amfAR Appoints New Leadership as AIDS Research Organization Extends Its Global Reach
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting